Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) today announced that at a Special Meeting held on May 21, 2013, its shareholders approved the proposals related to the planned acquisition of stem cell related assets from Geron Corporation by BioTime’s subsidiary Asterias Biotherapeutics, Inc. (“Asterias”). Each of the proposals received at least 32,459,164 votes in favor from the 34,450,307 shares that were represented and voted, in person or by proxy, at the meeting. Additional information concerning the proposals approved at the Special Meeting and the vote totals can be found in a Form 8-K that BioTime has filed with the Securities and Exchange Commission.
Help employers find you! Check out all the jobs and post your resume.